Skip to content


Executive management


Sarah Fredriksson

Chief Executive Officer

In current position since 2017.

Education: Ph.D. in Biochemistry in 1999 and M.Sc. in Chemistry in 1993 from the Faculty of Engineering (LTH), Lund University.

Experience and prior assignments: Sarah Fredriksson founded Genovis AB and during her time as CEO for more than 15 years, Genovis’ product concept was developed and launched and the company was listed on First North, Nasdaq OMX Nordic. She has many years of experience from research and development in biotech from both academia and industry. For several years now, she has been active as an entrepreneur, CEO and board member in unlisted and listed life science companies such as Genovis AB (publ), Edvince AB, Geccodots AB, Respiratorius AB (publ) as well as the board of Lund University and the national non-profit association for the life science industry SwedenBIO AB.

Other current assignments: Board member of LU Holding, Faculty of Engineering (LTH).

Born: 1968

Holdings: 33,030 shares* and 68,602 warrants**.

Gustaf Albèrt


In current position since 2023.

Education: Bachelor of Economics and Master of Science in International Accounting and Auditing from the School of Economics at the University of Gothenburg.

Experience and prior assignments: Gustaf Albèrt has many years of experience working as a CFO in both public and private companies and has worked as an auditor at Deloitte and Arthur Andersson. He also has experience from pharmaceutical development, as well as raising capital and IPOs.

Born: 1968

Holdings: 24,010 warrants**.


Other management


Martin Johansson

Chief Discovery Officer

In current position since 2019.

Education: Ph.D. in Organic Chemistry 2002, Associate Professor in Organic Chemistry 2007, and Master’s degree in Chemical Engineering 1997, Lund University.

Experience and prior assignments: Martin Johansson has been involved with Aqilion since 2012 as project manager for the former project company Glactone Pharma AB. He has 20 years of experience in medicinal chemistry and preclinical drug discovery and development. Previously, he has held the position of Chief Scientific Officer at Respiratorius AB and Senior Research Scientist at AstraZeneca, Discovery R&D.

Other current assignments:

Born: 1971

Holdings: 21,000 shares* and 24,100 warrants**.


Fredrik Lindgren

Vice President Chief Business Officer

In current position since 2018.

Education: Ph.D. in Chemistry, 1994 and B.Sc. in Chemistry 1989, Umeå University.

Experience and prior assignments: Fredrik Lindgren’s background is in the pharmaceutical industry, with experience from key positions in areas such as business development processes at AstraZeneca and LEO Pharma. among others. Most recently he held the position of Senior Director, Head of Global Business Development, at LEO Pharma.

Other current assignments:

Born: 1967

Holdings: 26,000 shares* and 24,100 warrants**.

Anneli Tinnerholm


In current position since 2022.

Education: Bachelor of Medical Science in Medical Biology, Linköping University, studies in clinical drug development at Uppsala University.

Experience and prior assignments: Anneli Tinnerholm has more than 10 years of experience from clinical trials as Clinical Research Associate and Clinical Trial Project Manager. She has held several operational positions in the CRO companies NORMA and LINK Medical, followed by an advisory clinical project management role at SDS Life Science with focus on smaller pharma and biotech companies. Anneli has gained a broad competence within clinical operations from FIH (first in humans) and Phase I to Phase IV clinical trials in several indications and therapy areas.

Other current assignments:

Born: 1986

Holdings: 4,550 shares* and 21,011 warrants**.


Johan Lund

Vice President Chief Scientific Officer

In current position since 2021.

Education: M.D., Ph.D. 1986 Karolinska Institutet; Post-doctoral studies 1987-1989 UT Southwestern Medical Center, Texas; Associate Professor 1990 Karolinska Institutet; Professor 1996 University of Bergen.

Experience and prior assignments: Dr. Johan Lund has many years of experience from executive positions in pharmaceutical research and development. He is the CEO and founder of KyNexis Medicine Development AB and the founder of MBS Pharma AB. Most recently, he was Vice President of Translational R&D at Celgene, in Cambridge, Massachusetts, USA, with responsibility for early research and development in inflammation and immunology. Previous positions include Chief Scientific Officer, Immunoscience Research Unit at Pfizer, Cambridge, Massachusetts, as well as 14 years at AstraZeneca in executive positions in Sweden and the UK as Vice President CNS & Pain Innovative Medicines Science and Vice President Respiratory and Inflammation Research. Previously Chairman of the Board at AQILION AB.

Other current assignments: Chairman of the board NEOGAP Therapeutics AB and Board member of Olink Proteomics AB, Neuventis Therapeutics AB and MBS Pharma AB.

Born: 1957

Holdings: 41,160 shares* and 21 011 warrants**.


Jan Törnell

Vice President Chief Medical Scientist

In current position since 2018.

Education: Medical degree, University of Gothenburg, 1985; Ph.D. in Physiology, Faculty of Medicine, Gothenburg, 1990; and Associate Professor in Physiology, 1992.

Experience and prior assignments: Jan Törnell has been involved with Aqilion/P.U.L.S. since 2012 through board positions in portfolio companies, as project manager/CEO and as an innovator. He also has many years of experience in executive positions in the pharmaceutical industry internationally. He has previously held the position of Global Vice President Strategy, Oncology & Infection and Global VP Translational Science at AstraZeneca and was Professor at the Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg.

Other current assignments: Chairman of the Board of Glactone Pharma AB, and Innoext AB; Board member of Abliva AB

Born: 1960

Holdings: 7,644 shares* and 21,011 warrants**.

Holdings updated as of December 31, 2023.
* Own or related natural or legal person’s holding of shares and other financial instruments in the company.
** Aqilion AB (publ) warrants program series 2023/2027-A